Search results
Results from the WOW.Com Content Network
This is the list of Schedule III controlled substances in the United States as defined in section 202 of the Controlled Substances Act (21 U.S.C. § 812) and 21 CFR 1308.13. The following findings are required for substances to be placed in this schedule:
This list is not limited to drugs that were ever approved by the FDA. Some of them (lumiracoxib, rimonabant, tolrestat, ximelagatran and ximelidine, for example) were approved to be marketed in Europe but had not yet been approved for marketing in the US, when side effects became clear and their developers pulled them from the market.
This is a list of opioids, opioid antagonists and inverse agonists. Opium and poppy straw derivatives. Seedhead of opium poppy with white latex.
This is the list of Schedule II controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required, by section 202 of that Act, for substances to be placed in this schedule: The drug or other substance has a high potential for abuse.
The approval could mean higher sales for Lilly's second-biggest drug, but the question is by how much. Doctors have already been heavily prescribing the drug as a painkiller, according to the FDA ...
This is the list of Schedule IV controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required for substances to be placed in this schedule: [2] The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule III.
The test, AvertD, is developed by privately held SOLVD Health. The FDA granted the approval to AutoGenomics, a unit that SOLVD acquired in 2019. AvertD is intended to be used before the first use ...
On Thursday, the FDA proposed removing oral phenylephrine from the list of approved active ingredients for over-the-counter (OTC) nasal decongestants, citing concerns over its effectiveness. After ...